- •PROGRESS IN BRAIN RESEARCH
- •List of Contributors
- •Preface
- •Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects
- •Introduction
- •Prevalence of glaucoma
- •PAC suspect
- •PACG
- •Incidence of glaucoma
- •Blinding effects of glaucoma
- •Abbreviations
- •Acknowledgment
- •References
- •Predictive models to estimate the risk of glaucoma development and progression
- •Risk assessment in ocular hypertension and glaucoma
- •Risk factors for glaucoma development
- •Intraocular pressure
- •Corneal thickness
- •Cup/disc ratio and pattern standard deviation
- •The need for predictive models
- •Predictive models for glaucoma development
- •Predictive models for glaucoma progression
- •Limitations of predictive models
- •References
- •Intraocular pressure and central corneal thickness
- •Main text
- •References
- •Angle-closure: risk factors, diagnosis and treatment
- •Introduction
- •Mechanism
- •Other causes of angle closure
- •Risk factors
- •Age and gender
- •Ethnicity
- •Ocular biometry
- •Genetics
- •Diagnosis
- •Acute primary angle closure
- •Angle assessment in angle closure
- •Gonioscopy technique
- •Ultrasound biomicroscopy (UBM)
- •Scanning peripheral anterior chamber depth analyzer (SPAC)
- •Management
- •Acute primary angle closure
- •Medical therapy
- •Argon laser peripheral iridoplasty (ALPI)
- •Laser peripheral iridotomy (PI)
- •Lens extraction
- •Monitoring for subsequent IOP rise in eyes with APAC
- •Fellow eye of APAC
- •Chronic primary angle-closure glaucoma (CACG)
- •Laser peripheral iridotomy
- •Laser iridoplasty
- •Medical therapy
- •Trabeculectomy
- •Lens extraction
- •Combined lens extraction and trabeculectomy surgery
- •Goniosynechialysis
- •Summary
- •List of abbreviations
- •References
- •Early diagnosis in glaucoma
- •Introduction
- •History and examination
- •Quantitative tests and the diagnostic process
- •Pretest probability
- •Test validity
- •Diagnostic test performance
- •Posttest probability
- •Combing test results
- •Selective tests of visual function
- •Early glaucoma diagnosis from quantitative test results
- •Progression to make a diagnosis
- •Conclusions
- •Abbreviations
- •References
- •Monitoring glaucoma progression
- •Introduction
- •Monitoring structural damage progression
- •Monitoring functional damage progression
- •Abbreviations
- •References
- •Standard automated perimetry and algorithms for monitoring glaucoma progression
- •Standard automated perimetry
- •Global indices
- •HFA: MD, SF, PSD, CPSD
- •Octopus indices: MD, SF, CLV
- •OCTOPUS seven-in-one report (Fig. 2)
- •SAP VF assessment: full-threshold strategy
- •SAP VF defects assessment: OHTS criteria
- •SAP VF defects assessment: AGIS criteria
- •SAP VF defects assessment: CIGTS
- •Fastpac
- •Swedish interactive threshold algorithm
- •SAP VF assessment: the glaucoma staging system
- •SAP: interocular asymmetries in OHTS
- •SAP, VF progression
- •SAP: the relationship to other functional and structural diagnostic tests in glaucoma
- •SAP, FDP-Matrix
- •SAP, SWAP, HPRP, FDT
- •SAP: the relationship between function and structure
- •SAP, confocal scanning laser ophthalmoscopy, SLP-VCC
- •SAP, optical coherence tomography
- •SAP and functional magnetic resonance imaging
- •References
- •Introduction
- •Retinal ganglion cells: anatomy and function
- •Is glaucoma damage selective for any subgroup of RGCs?
- •Segregation
- •Isolation
- •FDT: rationale and perimetric techniques
- •SWAP: rationale and perimetric techniques
- •FDT: clinical data
- •SWAP: clinical data
- •Clinical data comparing FDT and SWAP
- •Conclusions
- •References
- •Scanning laser polarimetry and confocal scanning laser ophthalmoscopy: technical notes on their use in glaucoma
- •The GDx scanning laser polarimeter
- •Serial analysis
- •Limits
- •The Heidelberg retinal tomograph
- •Limits
- •Conclusions
- •References
- •The role of OCT in glaucoma management
- •Introduction
- •How OCT works
- •How OCT is performed
- •Evaluation of RNFL thickness
- •Evaluation of optic disc
- •OCT in glaucoma management
- •New perspective
- •Abbreviations
- •References
- •Introduction
- •Technology
- •Visual stimulation
- •Reproducibility and habituation of RFonh
- •Retinal neural activity as assessed from the electroretinogram (ERG)
- •The Parvo (P)- and Magno (M)-cellular pathways
- •Physiology
- •Magnitude and time course of RFonh in humans
- •Varying the parameters of the stimulus on RFonh
- •Luminance versus chromatic modulation
- •Frequency
- •Effect of pattern stimulation
- •Neurovascular coupling in humans
- •Clinical application
- •RFonh in OHT and glaucoma patients
- •Discussion
- •FLDF and neurovascular coupling in humans
- •Comments on clinical application of FLDF in glaucoma
- •Conclusions and futures directions
- •Acknowledgements
- •References
- •Advances in neuroimaging of the visual pathways and their use in glaucoma
- •Introduction
- •Conventional MR imaging and the visual pathways
- •Diffusion MR imaging
- •Functional MR imaging
- •Proton MR spectroscopy
- •References
- •Primary open angle glaucoma: an overview on medical therapy
- •Introduction
- •When to treat
- •Whom to treat
- •Genetics
- •Race
- •Ocular and systemic abnormalities
- •Tonometry and pachymetry
- •How to treat
- •Beta-blockers
- •Prostaglandins
- •Alpha-agonists
- •Carbonic anhydrase inhibitors (CAIs)
- •Myotics
- •Fixed combinations
- •References
- •The treatment of normal-tension glaucoma
- •Introduction
- •Epidemiology
- •Clinical features
- •Optic disk
- •Central corneal thickness
- •Disease course
- •Risk factors
- •Intraocular pressure
- •Local vascular factors
- •Immune mechanisms
- •Differential diagnosis
- •Diagnostic evaluation
- •Therapy
- •IOP reduction
- •Systemic medications
- •Neuroprotection
- •Noncompliance
- •Genetics of NTG
- •Abbreviations
- •References
- •The management of exfoliative glaucoma
- •Introduction
- •Epidemiology
- •Ocular and systemic associations
- •Ocular associations
- •Systemic associations
- •Pathogenesis of exfoliation syndrome
- •Mechanisms of glaucoma development
- •Management
- •Medical therapy
- •Laser surgery
- •Operative surgery
- •Future treatment of exfoliation syndrome and exfoliative glaucoma
- •Treatment directed at exfoliation material
- •References
- •Laser therapies for glaucoma: new frontiers
- •Background
- •Laser iridotomy
- •Indications
- •Contraindications
- •Patient preparation
- •Technique
- •Nd:YAG laser iridectomy
- •Argon laser iridectomy
- •Complications
- •LASER trabeculoplasty
- •Treatment technique
- •Mechanism of action
- •Indications for treatment
- •Contraindications to treatment
- •Patient preparation and postoperative follow-up
- •Complications of the treatment
- •Selective laser trabeculoplasty
- •Results
- •LASER iridoplasty
- •Indications
- •Contraindications
- •Treatment technique
- •Complications
- •LASER cyclophotocoagulation
- •Introduction
- •Indications and contraindications
- •Patient preparation
- •Transpupillary cyclophotocoagulation
- •Endoscopic cyclophotocoagulation
- •Transscleral cyclophotocoagulation
- •Transscleral noncontact cyclophotocoagulation
- •Transscleral contact cyclophotocoagulation
- •Complications
- •Excimer laser trabeculotomy
- •References
- •Modulation of wound healing during and after glaucoma surgery
- •The process of wound healing
- •Using surgical and anatomical principles to modify therapy
- •Growth factors
- •Cellular proliferation and vascularization
- •Cell motility, matrix contraction and synthesis
- •Drug delivery
- •Future directions: total scarring control and tissue regeneration
- •Acknowledgments
- •References
- •Surgical alternative to trabeculectomy
- •Introduction
- •Deep sclerectomy
- •Viscocanalostomy
- •Conclusions
- •References
- •Modern aqueous shunt implantation: future challenges
- •Background
- •Current shunts and factors affecting their function
- •Shunt-related factors
- •Surface area
- •Plate material
- •Valved versus non-valved
- •Commercially available devices
- •Comparative studies
- •Patient and ocular factors
- •Severity of glaucoma damage
- •Tolerance of topical ocular hypotensive medications
- •Aqueous hyposecretion
- •Previous ocular surgery
- •Scleral thinning
- •Patient cooperation for and tolerance of potential slit-lamp interventions
- •Future challenges
- •Predictability
- •Cataract formation
- •The long-term effect on the cornea
- •References
- •Model systems for experimental studies: retinal ganglion cells in culture
- •Mixed RGCs in culture
- •Retinal explants
- •Glial cultures
- •RGC-5 cells
- •Differentiation of RGC-5 cells
- •RGC-5 cell neurites
- •Advantages and disadvantages of culture models
- •References
- •Rat models for glaucoma research
- •Rat models for glaucoma research
- •Use of animal models for POAG
- •Suitability of the rat for models of optic nerve damage in POAG
- •Methods for measuring IOP in rats
- •General considerations for measuring IOP in rats
- •Assessing optic nerve and retina damage
- •Experimental methods of producing elevated IOP
- •Laser treatment of limbal tissues
- •Episcleral vein cautery
- •Conclusions
- •Abbreviations
- •Acknowledgements
- •References
- •Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and neuroprotection
- •Introduction
- •The mouse as a model system
- •Mice are suitable models for studying IOP elevation in glaucoma
- •Tools for glaucoma research
- •Accurate IOP measurements are fundamental to the study of glaucoma
- •The future of IOP assessment
- •Assessment of RGC function
- •Mouse models of glaucoma
- •Primary open-angle glaucoma
- •MYOC
- •OPTN
- •Strategies for developing new models of POAG
- •Developmental glaucoma
- •Pigmentary glaucoma
- •Experimentally induced models of glaucoma
- •Mouse models to characterize processes involved in glaucomatous neurodegeneration
- •Similar patterns of glaucomatous damage occur in humans and mice
- •The lamina cribrosa is an important site of early glaucomatous damage
- •An insult occurs to the axons of RGCs within the lamina in glaucoma
- •What is the nature of the insult at the lamina?
- •Other changes occur in the retina in glaucoma
- •PERG and complement
- •Using mouse models to develop neuroprotective strategies
- •Somal protection
- •Axonal protection
- •Erythropoietin administration
- •Radiation-based treatment
- •References
- •Clinical trials in neuroprotection
- •Introduction
- •Methods of clinical studies
- •Issues in the design and conduct of clinical trials
- •Clinical trials of neuroprotection
- •Clinical trials of neuroprotection in ophthalmology
- •Endpoints
- •Neuroprotection and glaucoma
- •Conclusions
- •Abbreviations
- •References
- •Pathogenesis of ganglion ‘‘cell death’’ in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria
- •Introduction
- •Retinal ganglion cells and mitochondria
- •Possible causes for ganglion cell death in glaucoma
- •Mitochondrial functions and apoptosis
- •Mitochondrial function enhancement and the attenuation of ganglion cell death
- •Creatine
- •Nicotinamide
- •Epigallocatechin gallate
- •Conclusion
- •References
- •Astrocytes in glaucomatous optic neuropathy
- •Introduction
- •Quiescent astrocytes
- •Reactive astrocytes in glaucoma
- •Signal transduction in glaucomatous astrocytes
- •Protein tyrosine kinases (PTKs)
- •Serine/threonine protein mitogen-activated kinases (MAPKs)
- •G protein-coupled receptors
- •Ras superfamily of small G proteins
- •Astrocyte migration in the glaucomatous optic nerve head
- •Cell adhesion of ONH astrocytes
- •Connective tissue changes in the glaucomatous optic nerve head
- •Extracellular matrix synthesis by ONH astrocytes
- •Extracellular matrix degradation by reactive astrocytes
- •Oxidative stress in ONH astrocytes
- •Conclusions
- •Acknowledgments
- •References
- •Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation
- •Glaucoma as a neurodegenerative disease
- •Oxidative stress and free radicals
- •Excessive glutamate, increased calcium levels, and excitotoxicity
- •Deprivation of neurotrophins and growth factors
- •Abnormal accumulation of proteins
- •Pharmacological neuroprotection for glaucoma
- •Protection of the retinal ganglion cells involves the immune system
- •Searching for an antigen for potential glaucoma therapy
- •Concluding remarks
- •References
- •Oxidative stress and glaucoma: injury in the anterior segment of the eye
- •Introduction
- •Oxidative stress
- •Trabecular meshwork
- •IOP increase and free radicals
- •Glaucomatous cascade
- •Nitric oxide and endothelins
- •Extracellular matrix
- •Metalloproteinases
- •Other factors of interest
- •Therapeutic and preventive substances of interest in glaucoma
- •Ginkgo biloba extract
- •Green tea
- •Ginseng
- •Memantine and its derivates
- •Conclusions
- •Abbreviations
- •References
- •Conclusions on neuroprotective treatment targets in glaucoma
- •Acknowledgments
- •References
- •Involvement of the Bcl2 gene family in the signaling and control of retinal ganglion cell death
- •Introduction
- •Intrinsic apoptosis vs. extrinsic apoptosis
- •The Bcl2 family of proteins
- •The requirement of BAX for RGC soma death
- •BH3-only proteins and the early signaling of ganglion cell apoptosis
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •Assessment of neuroprotection in the retina with DARC
- •Introduction
- •DARC
- •Introducing the DARC technique
- •Annexin 5-labeled apoptosis and ophthalmoloscopy
- •Detection of RGC apoptosis in glaucoma-related animal models with DARC
- •Assessment of glutamate modulation with DARC
- •Glutamate at synaptic endings
- •Glutamate excitotoxicity in glaucoma
- •Assessment of coenzyme Q10 in glaucoma-related models with DARC
- •Summary
- •Abbreviations
- •Acknowledgment
- •References
- •Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection
- •Introduction
- •The endocannabinoid system in the eye
- •The IOP-lowering effects of endocannabinoids
- •Endocannabinoids and neuroprotection
- •Conclusions
- •References
- •Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration
- •Retinal ganglion cells, retino-geniculate neurons
- •Lateral geniculate nucleus
- •Mechanisms of RGC injury in glaucoma
- •Transsynaptic degeneration of the lateral geniculate nucleus in glaucoma
- •Neural degeneration in magno-, parvo-, and koniocellular LGN layers
- •Visual cortex in glaucoma
- •Neuropathology of glaucoma in the visual pathways in the human brain
- •Mechanisms of glaucoma damage in the central visual pathways
- •Implications of central visual system injury in glaucoma
- •Conclusion
- •Acknowledgments
- •References
- •Clinical relevance of optic neuropathy
- •Is there a remodeling of retinal circuitry?
- •Behavioral consequences of glaucoma
- •Glaucoma as a neurodegenerative disease versus neuroplasticity and adaptive changes
- •Future directions
- •Acknowledgment
- •References
- •Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma
- •Introduction
- •Channel properties of NMDA receptors correlated with excitotoxicity
- •Downstream signaling cascades after overactivation of NMDA receptors
- •Relevance of excitotoxicity to glaucoma
- •Therapeutic approaches to prevent RGC death by targeting the pathways involved in NMDA excitotoxicity
- •Drugs targeting NMDA receptors
- •Kinetics of NMDA receptor antagonists
- •Memantine
- •NitroMemantines
- •Drugs targeting downstream signaling molecules in NMDA-induced cell death pathways
- •p38 MAPK inhibitors
- •Averting caspase-mediated neurodegeneration
- •Abbreviations
- •Acknowledgments
- •References
- •Stem cells for neuroprotection in glaucoma
- •Introduction
- •Glaucoma as a model of neurodegenerative disease
- •Why use stem cells for neuroprotective therapy?
- •Stem cell sources
- •Neuroprotection by transplanted stem cells
- •Endogenous stem cells
- •Key challenges
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cells
- •Introduction
- •Glaucoma and the RGCs
- •Are other retinal cells affected in glaucoma?
- •Retinal ischemia related glaucoma
- •Excitotoxicity and the retina
- •Signal transduction
- •NMDA receptor antagonists and CaMKII
- •Caspase-3 activation in NMDA-induced retinal cell death and its inhibition by m-AIP
- •BDNF and neuroprotection of RGCs
- •Summary and conclusions
- •Abbreviations
- •Acknowledgments
- •References
- •Evidence of the neuroprotective role of citicoline in glaucoma patients
- •Introduction
- •Patients: selection and recruitment criteria
- •Pharmacological treatment protocol
- •Methodology of visual function evaluation: electrophysiological examinations
- •PERG recordings
- •VEP recordings
- •Statistic evaluation of electrophysiological results
- •Electrophysiological (PERG and VEP) responses in OAG patients after the second period of evaluation
- •Effects of citicoline on retinal function in glaucoma patients: neurophysiological implications
- •Effects of citicoline on neural conduction along the visual pathways in glaucoma patients: neurophysiological implications
- •Possibility of neuroprotective role of citicoline in glaucoma patients
- •Conclusive remarks
- •Abbreviations
- •References
- •Neuroprotection: VEGF, IL-6, and clusterin: the dark side of the moon
- •Neuroprotection: VEGF-A, a shared growth factor
- •VEGF-A isoforms
- •VEGF-A receptors
- •Angiogenesis, mitogenesis, and endothelial survival
- •Neurotrophic and neuroprotective effect
- •Intravitreal VEGF inhibition therapy and neuroretina toxicity
- •Neuroprotection: clusterin, a multifunctional protein
- •Clusterin/ApoJ: a debated physiological role
- •Clusterin and diseases
- •Clusterin and the nervous system
- •Neuroprotection: IL-6, VEGF, clusterin, and glaucoma
- •Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection
- •Introduction
- •Ischemia model
- •Neuroprotective effect of Coenzyme Q10 against cell loss yielded by transient ischemia in the RGC layer
- •Retinal ischemia and glutamate
- •Coenzyme Q10 minimizes glutamate increase induced by ischemia/reperfusion
- •Summary
- •Acknowledgment
- •References
- •17beta-Estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat
- •Methods
- •Morphometric analysis
- •Microdialysis
- •Drug application
- •Statistical analysis
- •Results
- •17beta-Estradiol pretreatment minimizes RGC loss
- •Discussion
- •Acknowledgment
PROGRESS IN BRAIN RESEARCH
VOLUME 173
GLAUCOMA: AN OPEN-WINDOW TO NEURODEGENERATION AND NEUROPROTECTION
EDITED BY
CARLO NUCCI
Ophthalmological Unit, Department of Biopathology and Diagnostic Imaging, University of Rome ‘‘Tor Vergata’’, Rome, Italy
NEVILLE N. OSBORNE
Nuffield Laboratory of Ophthalmology, University of Oxford, Oxford, UK
GIACINTO BAGETTA
Department of Pharmacobiology, University of Calabria, Cosenza, Italy
LUCIANO CERULLI
Ophthalmological Unit, Department of Biopathology and Diagnostic Imaging, University of Rome ‘‘Tor Vergata’’, Rome, Italy
AMSTERDAM – BOSTON – HEIDELBERG – LONDON – NEW YORK – OXFORD PARIS – SAN DIEGO – SAN FRANCISCO – SINGAPORE – SYDNEY – TOKYO
Elsevier
30 Corporate Drive, Suite 400, Burlington, MA 01803, USA Linacre House, Jordan Hill, Oxford OX2 8DP, UK
Radarweg 29, PO Box 211, 1000 AE Amsterdam, The Netherlands
First edition 2008
Copyright r 2008 Elsevier B.V. All rights reserved
No part of this publication may be reproduced, stored in a retrieval system
or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher
Permissions may be sought directly from Elsevier’s Science & Technology Rights Department in Oxford, UK: phone (+44) (0) 1865 843830; fax (+44) (0) 1865 853333; email: permissions@elsevier.com. Alternatively you can submit your request online by visiting the Elsevier web site at http://www.elsevier.com/locate/permissions, and selecting
Obtaining permission to use Elsevier material
Notice
No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made
British Library Cataloguing in Publication Data
A catalogue record for this book is available from the British Library
Library of Congress Cataloging-in-Publication Data
A catalog record for this book is available from the Library of Congress
ISBN: 978-0-444-53256-5 (this volume)
ISSN: 0079-6123 (Series)
For information on all Elsevier publications visit our website at books.elsevier.com
Printed and bound in Hungary
08 09 10 11 12 10 9 8 7 6 5 4 3 2 1
List of Contributors
N. Amerasinghe, Singapore National Eye Centre, Singapore, Singapore
A.M. Angrisani, Ophthalmology Unit, Association Columbus Clinic, Catholic University of Rome, Rome, Italy
P. Aragona, Section of Ophthalmology, Department of Surgical Specialities, Azienda Ospedaliera Universitaria Policlinico G. Martino, Messina, Italy
T. Aung, Singapore National Eye Centre, Singapore, Singapore
G. Bagetta, Department of Biomedical Sciences, University of Teramo, Teramo; Department of Pharmacobiology; Section of Neuropharmacology of Normal and Pathological Neuronal Plasticity, University Center for Adaptive Disorders and Headache (UCHAD), University of Calabria, Arcavacata di Rende (Cosenza), Italy
E. Balestrazzi, Department of Ophthalmology, A. Gemelli University Hospital, Catholic University of the Sacred Heart, Rome, Italy
M. Bari, Department of Experimental Medicine and Biochemical Sciences, University of Rome ‘‘Tor Vergata’’, Rome, Italy
K. Barton, Moorfields Eye Hospital; Department of Epidemiology, Institute of Ophthalmology, University College London, London, UK
S.Brocchini, ORB (Ocular Repair and Regeneration Biology Research Unit), National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK; The School of Pharmacy, University of London, London, WC1N 1AX, UK
P. Brusini, Department of Ophthalmology, Santa Maria della Misericordia Hospital, Udine, Italy N.D. Bull, Cambridge Centre for Brain Repair, University of Cambridge, Cambridge, UK
F. Cantatore, Glaucoma Center, Department of Ophthalmology, University of Bari, Bari, Italy J. Caprioli, Jules Stein Eye Institute, UCLA, Los Angeles, CA, USA
R.G. Carassa, Department of Ophthalmology, University Hospital S. Raffaele, Milano, Italy
F. Cavaliere, Department of Pharmacobiology, University of Calabria, Arcavacata di Rende, Italy
C.Cedrone, Physiopathological Optics, Department of Biopathology and Diagnostic Imaging, University of Rome ‘‘Tor Vergata’’, Rome, Italy
M. Centofanti, Biopathology Department; Department of Ophthalmology, University of Rome ‘‘Tor Vergata’’; G.B. Bietti Eye Foundation, IRCCS, Rome, Italy
W.O. Cepurna, Casey Eye Institute, Oregon Health & Science University, Portland, OR, USA
A.Cerulli, Physiopathological Optics, Department of Biopathology and Diagnostic Imaging, University of Rome ‘‘Tor Vergata’’, Rome; Department of Pharmacobiology, University of Calabria, Arcavacata di Rende, Italy
M. Cesareo, Physiopathological Optics, Department of Biopathology and Diagnostic Imaging, University of Rome ‘‘Tor Vergata’’, Rome, Italy
N.G.F. Cooper, Department of Anatomical Sciences and Neurobiology, University of Louisville School of Medicine, Louisville, KY, USA
v
vi
G. Coppola, Ophthalmology Unit, Association Columbus Clinic, Catholic University of Rome, Rome, Italy
M.T. Corasaniti, Department of Pharmacobiological Sciences, University ‘‘Magna Graecia’’ of Catanzaro, Catanzaro; Department of Biopathology; ‘‘Mondino-Tor Vergata’’ Center for Experimental Neurobiology, University of Rome ‘‘Tor Vergata’’, Rome, Italy
M.F. Cordeiro, Glaucoma & Retinal Degeneration Research Group, UCL Institute of Ophthalmology; The Glaucoma Research Group, Western Eye Hospital, London, UK
V. Cozzolino, Department of Diagnostic Imaging and Interventional Radiology, University of Rome ‘‘Tor Vergata’’, Rome, Italy
A. Dahlmann-Noor, ORB (Ocular Repair and Regeneration Biology Research Unit), National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK
P.V. Desai, Jules Stein Eye Institute, UCLA, Los Angeles, CA, USA
B. Falsini, Istituto di Oftalmologia, Universita’ Cattolica del S. Cuore, Roma, Italy
W. Fan, Department of Anatomical Sciences and Neurobiology, University of Louisville School of Medicine, Louisville, KY, USA
E. Fazzi, IRCCS Fondazione Istituto Neurologico ‘‘C. Mondino’’, Pavia, Italy
A. Ferreras, Department of Ophthalmology, Miguel Servet University, Zaragoza, Spain
F.Ferreri, Section of Ophthalmology, Department of Surgical Specialities, Azienda Ospedaliera Universitaria Policlinico G. Martino, Messina, Italy
G.Ferreri, Section of Ophthalmology, Department of Surgical Specialities, Azienda Ospedaliera Universitaria Policlinico G. Martino, Messina, Italy
P. Ferreri, Glaucoma Center, Department of Ophthalmology, University of Bari, Bari, Italy
R. Floris, Department of Diagnostic Imaging and Interventional Radiology, University of Roma ‘‘Tor Vergata’’, Rome, Italy
P. Fogagnolo, G.B. Bietti Foundation – IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Rome, Italy
F.G. Garaci, Department of Diagnostic Imaging and Interventional Radiology, University of Rome ‘‘Tor Vergata’’; IRCCS San Raffaele Pisana, Rome, Italy
D.F. Garway-Heath, NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK; G.B. Bietti Foundation – IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Rome, Italy
F. Gaudiello, Department of Diagnostic Imaging and Interventional Radiology, University of Rome ‘‘Tor Vergata’’, Rome, Italy
S. Georgoulas, The School of Pharmacy, University of London, London, WC1N 1AX, UK; ORB (Ocular Repair and Regeneration Biology Research Unit), National Institute for Health Research Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK
M. Gliozzi, Department of Pharmacobiological Sciences, University ‘‘Magna Graecia’’of Catanzaro, Catanzaro, Italy
E. Goodyear, Department of Ophthalmology, University of Montreal, Montreal, Canada
L.Guo, Glaucoma & Retinal Degeneration Research Group, UCL Institute of Ophthalmology, London, UK
N. Gupta, Department of Ophthalmology and Vision Sciences; Department of Laboratory Medicine and Pathobiology, Keenan Research Centre at the Li Ka Shing, Knowledge Institute of St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada
M.R. Hernandez, Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
vii
D.K. Heuer, Department of Ophthalmology, Medical College of Wisconsin Milwaukee; Froedtert & Medical College of Wisconsin, Eye Institute, Milwaukee, WI 53226, USA
G.R. Howell, The Jackson Laboratory, Bar Harbor, ME, USA
A.Izzotti, Department of Health Sciences, Faculty of Medicine, University of Genoa, Genoa, Italy S.W.M. John, The Jackson Laboratory; The Howard Hughes Medical Institute, Bar Harbor, ME;
Department of Ophthalmology, Tufts University of Medicine, Boston, MA, USA
E.Johnson, Casey Eye Institute, Oregon Health & Science University, Portland, OR, USA T.V. Johnson, Cambridge Centre for Brain Repair, University of Cambridge, Cambridge, UK P.T. Khaw, The School of Pharmacy, University of London, London, WC1N 1AX, UK
A.Laabich, Acucela Inc., Bothell, WA, USA
D. Lepore, Department of Ophthalmology, A. Gemelli University Hospital, Catholic University of the Sacred Heart, Rome, Italy
L.A. Levin, Department of Ophthalmology, University of Montreal, Montreal, Canada; Department of Opthamology and Visual Sciences, University of Wisconsion, Madison, USA
R.T. Libby, University of Rochester Eye Institute, University of Rochester Medical Center, Rochester, NY, USA
S.A. Lipton, Center for Neuroscience, Aging and Stem Cell Research, Burnham Institute for Medical Research, La Jolla, CA, USA
A.London, Department of Neurobiology, The Weizmann Institute of Science, Rehovot, Israel
A.Ludovici, Department of Diagnostic Imaging and Interventional Radiology, University of Rome
‘‘Tor Vergata’’, Rome, Italy
T. Lukas, Department of Molecular Pharmacology and Biological Chemistry, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
T. Lupattelli, Interventional Radiology Department, IRCCS Multimedica, Sesto San Giovanni, Milan, Italy M. Maccarrone, Department of Biomedical Sciences, University of Teramo, Teramo, Italy
R. Mancino, Physiopathological Optics, Department of Biopathology and Diagnostic Imaging, University of Rome ‘‘Tor Vergata’’, Rome, Italy
G. Manni, Department of Ophthalmology; Biopathology Department, University of Rome ‘‘Tor Vergata’’; G.B. Bietti Eye Foundation, IRCCS, Rome, Italy
K.R. Martin, Cambridge Centre for Brain Repair, University of Cambridge, Cambridge, UK
P. Mazzarelli, Department of Biopathology, Institute of Anatomic Pathology, University of Rome ‘‘Tor Vergata’’, Rome, Italy
F.A. Medeiros, Hamilton Glaucoma Center, University of California-San Diego, La Jolla, CA, USA H. Miao, Department of Ophthalmology, Feinberg School of Medicine, Northwestern University,
Chicago, IL, USA
F. Missiroli, Section of Ophthalmology, Department of Biopathology, University of Rome ‘‘Tor Vergata’’, Rome, Italy
A. Montepara, Glaucoma Center, Department of Ophthalmology, University of Bari, Bari, Italy J.C. Morrison, Casey Eye Institute, Oregon Health & Science University, Portland, OR, USA
L.A. Morrone, Department of Pharmacobiology; Section of Neuropharmacology of Normal and Pathological Neuronal Plasticity, University Center for Adaptive Disorders and Headache (UCHAD), University of Calabria, Arcavacata di Rende, Italy
R.W. Nickells, Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, WI, USA
C. Nucci, Ophthalmological Unit, Department of Biopathology and Diagnostic Imaging, University of Rome ‘‘Tor Vergata’’; Experimental Neuropharmacology Center, ‘‘Mondino-Tor Vergata’’, Fondazione C. Mondino-IRCCS, Rome, Italy
F. Oddone, G.B. Bietti Eye Foundation, IRCCS, Rome, Italy
viii
N. Orzalesi, Eye Clinic, Department of Medicine, Surgery and Odontoiatry, San Paolo Hospital, University of Milan, Milan, Italy
N.N. Osborne, Nuffield Laboratory of Ophthalmology, University of Oxford, Oxford, UK
M.M. Pagliara, Department of Ophthalmology, A. Gemelli University Hospital, Catholic University of the Sacred Heart, Rome, Italy
V. Parisi, G.B. Bietti Eye Foundation, IRCCS, Rome, Italy
N. Pasquale, University of Rome ‘‘La Sapienza’’, 2nd Faculty of Medicine, Rome, Italy A. Perdicchi, S. Andrea Hospital, Rome, Italy
S. Pucci, Department of Biopathology, Institute of Anatomic Pathology, University of Rome ‘‘Tor Vergata’’, Rome, Italy
L. Quaranta, Department of Ophthalmology, University of Brescia, Brescia, Italy
A. Quinto, Glaucoma Center, Department of Ophthalmology, University of Bari, Bari, Italy
S.Ranno, Eye Clinic, Department of Medicine, Surgery and Odontoiatry, San Paolo Hospital, University of Milan, Milan, Italy
S.M. Recupero, S. Andrea Hospital, 2nd Faculty of Medicine, University of Rome ‘‘La Sapienza’’, Rome, Italy
F.Regine, Section of Ophthalmology, Department of Biopathology, University of Rome ‘‘Tor Vergata’’, Rome, Italy
B.Ricci, Ophthalmology Unit, Association Columbus Clinic, Catholic University of Rome, Rome, Italy
F.Ricci, Section of Ophthalmology, Department of Biopathology, University of Rome ‘‘Tor Vergata’’, Rome, Italy
R.Ritch, New York Eye and Ear Infirmary, New York, NY, USA
C.E. Riva, Dipartimento di Discipline Chirurgiche, Rianomatorie e dei Trapianti ‘‘Antonio Valsalva’’, Universita´di Bologna, Bologna, Italy
L.Rombola`, Department of Pharmacobiology, University of Calabria, Arcavacata di Rende, Italy
L.Rossetti, Eye Clinic, Department of Medicine, Surgery and Odontoiatry, San Paolo Hospital, University of Milan, Milan, Italy
G.Ruggeri, Glaucoma Center, Department of Ophthalmology, University of Bari, Bari, Italy
R.Russo, Department of Pharmacobiology, University of Calabria, Arcavacata di Rende, Italy S.C. Sacca`, Division of Ophthalmology, St. Martino Hospital, Genoa, Italy
S.Sakurada, Department of Physiology and Anatomy, Tohoku Pharmaceutical University, Sendai, Japan
C.Sborgia, Glaucoma Center, Department of Ophthalmology, University of Bari, Bari, Italy
C.L. Schlamp, Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, WI, USA
M. Schwartz, Department of Neurobiology, The Weizmann Institute of Science, Rehovot, Israel
G.L. Scuderi, S. Andrea Hospital, 2nd Faculty of Medicine, University of Rome ‘‘La Sapienza’’, Rome, Italy
M. Seki, Center for Neuroscience, Aging and Stem Cell Research, Burnham Institute for Medical Research, La Jolla, CA, USA
S.J. Semaan, Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, WI, USA
S.C. Sharma, Departments of Ophthalmology, Cell Biology and Anatomy, New York Medical College, Valhalla, NY, USA
G. Simonetti, Department of Diagnostic Imaging and Interventional Radiology, University of Rome ‘‘Tor Vergata’’, Rome, Italy
A. Spano`, Ophthalmological Unit, Department of Biopathology and Diagnostic Imaging, University of Rome ‘‘Tor Vergata’’, Rome, Italy
ix
G. Tezel, Department of Ophthalmology and Visual Sciences; Department of Anatomical Sciences and Neurobiology, University of Louisville School of Medicine, Louisville, KY, USA
A. Tosto, Biopathology Department, University of Tor Vergata, Rome, Italy
M. Vetrugno, Glaucoma Center, Department of Ophthalmology, University of Bari, Bari, Italy
X. Wang, Department of Anatomical Sciences and Neurobiology, University of Louisville School of Medicine, Louisville, KY, USA
C. Watanabe, Department of Physiology and Anatomy, Tohoku Pharmaceutical University, Sendai, Japan R.N. Weinreb, Hamilton Glaucoma Center, University of California, San Diego, La Jolla, CA, USA S.M. Whitcup, Research and Development, Allergan, Inc., Irvine; Department of Ophthalmology, Jules
Stein Eye Institute, UCLA School of Medicine, Los Angeles, CA, USA
Y. Yu¨cel, Department of Ophthalmology and Vision Sciences; Department of Laboratory Medicine and Pathobiology, Keenan Research Centre at the Li Ka Shing, Knowledge Institute of St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada
L. Ziccardi, G.B. Bietti Eye Foundation, IRCCS, Rome, Italy
